Literature DB >> 10482917

Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: modulation by alpha2-adrenoceptors.

K E Wortley1, Z A Hughes, D J Heal, S C Stanford.   

Abstract

1. The effects of sibutramine (0.25 - 10 mg kg-1, i.p.) on extracellular noradrenaline concentration in the frontal cortex of halothane-anaesthetized rats were compared with those of d-amphetamine (1 - 3 mg kg-1, i.p.) using in vivo microdialysis. The role of presynaptic alpha2-adrenoceptors in modulating the effects of these drugs on extracellular noradrenaline concentration were also investigated by pretreating rats with the selective alpha2-adrenoceptor antagonist, RX821002. 2. Sibutramine induced a gradual and sustained increase in extracellular noradrenaline concentration. The dose-response relationship was described by a bell-shaped curve with a maximum effect at 0.5 mg kg-1. In contrast, d-amphetamine induced a rapid increase in extracellular noradrenaline concentration, the magnitude of which paralleled drug dose. 3. Pretreatment with the alpha2-adrenoceptor antagonist, RX821002 (dose 3 mg kg-1, i.p.) increased by 5 fold the accumulation of extracellular noradrenaline caused by sibutramine (10 mg kg-1) and reduced the latency of sibutramine to reach its maximum effect from 144 - 56 min. 4. RX821002-pretreatment increased by only 2.5 fold the increase in extracellular noradrenaline concentration caused by d-amphetamine alone (10 mg kg-1) and had no effect on the latency to reach maximum. 5. These findings support evidence that sibutramine acts as a noradrenaline uptake inhibitor in vivo and that the effects of this drug are blunted by indirect activation of presynaptic alpha2-adreno-ceptors. In contrast, the rapid increase in extracellular noradrenaline concentration induced by d-amphetamine is consistent with this being mainly due to an increase in Ca2+-independent release of noradrenaline.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482917      PMCID: PMC1566167          DOI: 10.1038/sj.bjp.0702720

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

Review 1.  Sibutramine: a review of the pharmacology of a novel anti-obesity agent.

Authors:  M J Stock
Journal:  Int J Obes Relat Metab Disord       Date:  1997-03

Review 2.  Noradrenergic mechanisms in the prefrontal cortex.

Authors:  D J Nutt; M D Lalies; L A Lione; A L Hudson
Journal:  J Psychopharmacol       Date:  1997       Impact factor: 4.153

3.  Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat.

Authors:  T Dennis; R L'Heureux; C Carter; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

4.  Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.

Authors:  H C Jackson; A M Needham; L J Hutchins; S E Mazurkiewicz; D J Heal
Journal:  Br J Pharmacol       Date:  1997-08       Impact factor: 8.739

5.  Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat.

Authors:  H C Jackson; M C Bearham; L J Hutchins; S E Mazurkiewicz; A M Needham; D J Heal
Journal:  Br J Pharmacol       Date:  1997-08       Impact factor: 8.739

6.  In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.

Authors:  C Gundlah; K F Martin; D J Heal; S B Auerbach
Journal:  J Pharmacol Exp Ther       Date:  1997-11       Impact factor: 4.030

7.  Modulation of catecholamine release by alpha 2-adrenoceptors and I1-imidazoline receptors in rat brain.

Authors:  J J Meana; M Herrera-Marschitz; M Goiny; R Silveira
Journal:  Brain Res       Date:  1997-01-09       Impact factor: 3.252

8.  The effects of peripheral D-amphetamine, 4-OH amphetamine, and epinephrine on maintained discharge in the locus coeruleus with reference to the modulation of learning and memory by these substances.

Authors:  R N Holdefer; R A Jensen
Journal:  Brain Res       Date:  1987-08-04       Impact factor: 3.252

9.  [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments.

Authors:  S C Cheetham; J A Viggers; S A Butler; M R Prow; D J Heal
Journal:  Neuropharmacology       Date:  1996-01       Impact factor: 5.250

10.  Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment.

Authors:  S M Florin; R Kuczenski; D S Segal
Journal:  Brain Res       Date:  1994-08-15       Impact factor: 3.252

View more
  6 in total

Review 1.  Central nervous system biogenic amine targets for control of appetite and energy expenditure.

Authors:  David L Nelson; Donald R Gehlert
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

2.  Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.

Authors:  Anne Marie D Axel; Jens D Mikkelsen; Henrik H Hansen
Journal:  Neuropsychopharmacology       Date:  2010-03-03       Impact factor: 7.853

3.  Amphetamine challenge decreases yohimbine binding to α2 adrenoceptors in Landrace pig brain.

Authors:  Anne M Landau; Doris J Doudet; Steen Jakobsen
Journal:  Psychopharmacology (Berl)       Date:  2012-01-07       Impact factor: 4.530

4.  Modulation of sibutramine-induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by alpha2-adrenoceptors.

Authors:  K E Wortley; D J Heal; S C Stanford
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  Differences in the mechanisms that increase noradrenaline efflux after administration of d-amphetamine: a dual-probe microdialysis study in rat frontal cortex and hypothalamus.

Authors:  Sandrine M Géranton; David J Heal; S Clare Stanford
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

Review 6.  Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology.

Authors:  David J Heal; Sharon L Smith
Journal:  J Psychopharmacol       Date:  2021-07-28       Impact factor: 4.562

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.